Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling
Open Access
- 3 June 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 836
- https://doi.org/10.3389/fphar.2020.00836
Abstract
In December 2019, reports of viral pneumonia came out of Wuhan city in Hubei province in China. In early 2020, the causative agent was identified as a novel coronavirus (CoV) sharing some sequence similarity with SARS-CoV that caused the severe acute respiratory syndrome outbreak in 2002. The new virus, named SARS-CoV-2, is highly contagious and spread rapidly across the globe causing a pandemic of what became known as coronavirus infectious disease 2019 (COVID-19). Early observations indicated that cardiovascular disease (CVD) patients are at higher risk of progression to severe respiratory manifestations of COVID-19 including acute respiratory distress syndrome. Moreover, further observations demonstrated that SARS-CoV-2 infection can induce de novo cardiac and vascular damage in previously healthy individuals. Here, we offer an overview of the proposed molecular pathways shared by the pathogenesis of CVD and SARS-CoV infections in order to provide a mechanistic framework for the observed interrelation. We examine the crosstalk between the renin-angiotensin-aldosterone system and mitogen activated kinase pathways that potentially links cardiovascular predisposition and/or outcome to SARS-CoV-2 infection. Finally, we summarize the possible effect of currently available drugs with known cardiovascular benefit on these pathways and speculate on their potential utility in mitigating cardiovascular risk and morbidity in COVID-19 patients.This publication has 128 references indexed in Scilit:
- ACE2 Deficiency Enhances Angiotensin II-Mediated Aortic Profilin-1 Expression, Inflammation and Peroxynitrite ProductionPLOS ONE, 2012
- ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertensionCardiovascular Research, 2011
- Regulation of ACE2 in cardiac myocytes and fibroblastsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targetsClinical Science, 2008
- Suppression of Coronavirus Replication by Inhibition of the MEK Signaling PathwayJournal of Virology, 2007
- Cardioprotective Mechanisms of Eplerenone on Cardiac Performance and Remodeling in Failing Rat HeartsHypertension, 2006
- Imatinib Attenuates End-Organ Damage in Hypertensive Homozygous TGR(mRen2)27 RatsHypertension, 2006
- Eplerenone Shows Renoprotective Effect by Reducing LOX-1–Mediated Adhesion Molecule, PKCε-MAPK-p90RSK, and Rho-Kinase PathwayHypertension, 2005
- Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cellsBiochemical and Biophysical Research Communications, 2004
- Hypertrophic agonists induce the binding of c-Fos to an AP-1 site in cardiac myocytes: implications for the expression of GLUT1Cardiovascular Research, 2003